Jane Bell Joins Mesoblast Board
August 18 2022 - 7:00AM
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in
allogeneic cellular medicines for inflammatory diseases, today
announced that it has appointed Jane Bell to its Board of
Directors. Ms Bell is a banking and finance lawyer with 22 years of
corporate finance expertise focussing on international investment
transactions in the United States, Canada, Australia and the United
Kingdom, including funds management, mergers, acquisitions, and
divestments. She has served as a non-executive Director in a
diverse range of highly regulated sectors including delivery of
healthcare, life sciences, medical research, and funds management.
Ms Bell currently serves as Deputy Chair of
Monash Health, one of Australia’s largest and most diverse public
health service delivering more than 3.46 million episodes of care
across an extensive network of hospitals, rehabilitation, aged
care, community health and mental health facilities and a former
Chair of Melbourne Health. From 2014 until 2021 she was a director
of U Ethical, Australia’s first ethical funds manager with over
$1.2B of funds under management, and a member of its Investment
Committee. She has also been a director of Hudson Institute of
Medical Research, is currently a director of Amplia Therapeutics,
and Chairs Advisory Groups for the Royal Australian and New Zealand
College of Obstetricians and Melbourne Genomics Health
Alliance.
Commenting on her appointment Ms Bell said “I
look forward to joining the Mesoblast Board at such an exciting
stage in the company’s transition to a commercial organization,
with its deep cell therapy product pipeline. The potential FDA
approval and launch in the US market of the first allogeneic cell
therapy is an incredibly exciting opportunity for me to be involved
with and I look forward to using my background and experience to
make a strong contribution.”
In other board changes, Shawn Tomasello will
retire after four years on the Board. Ms Tomasello said, “I am
confident that Mesoblast will successfully execute commercially on
its potential first product launch, and the promise of its leading
edge technology and I’ll be following closely from the
sidelines”.
Mesoblast Chairman Joseph Swedish welcomed Ms
Bell to the Board and thanked Ms Tomasello for her contributions.
Mr Swedish said “We are delighted to have Jane join Mesoblast as an
Independent Non-Executive Director. She has extensive corporate
finance experience and diverse involvement across a wide range of
healthcare and corporate finance organizations.”
About Mesoblast Mesoblast is a
world leader in developing allogeneic (off-the-shelf) cellular
medicines for the treatment of severe and life-threatening
inflammatory conditions. The Company has leveraged its proprietary
mesenchymal lineage cell therapy technology platform to establish a
broad portfolio of late-stage product candidates which respond to
severe inflammation by releasing anti-inflammatory factors that
counter and modulate multiple effector arms of the immune system,
resulting in significant reduction of the damaging inflammatory
process.
Mesoblast has a strong and extensive global
intellectual property portfolio with protection extending through
to at least 2041 in all major markets. The Company’s proprietary
manufacturing processes yield industrial-scale, cryopreserved,
off-the-shelf, cellular medicines. These cell therapies, with
defined pharmaceutical release criteria, are planned to be readily
available to patients worldwide.
Mesoblast is developing product candidates for
distinct indications based on its remestemcel-L and
rexlemestrocel-L allogeneic stromal cell technology platforms.
Remestemcel-L is being developed for inflammatory diseases in
children and adults including steroid refractory acute graft versus
host disease, biologic-resistant inflammatory bowel disease, and
acute respiratory distress syndrome. Rexlemestrocel-L is in
development for advanced chronic heart failure and chronic low back
pain. Two products have been commercialized in Japan and Europe by
Mesoblast’s licensees, and the Company has established commercial
partnerships in Europe and China for certain Phase 3 assets.
Mesoblast has locations in Australia, the United
States and Singapore and is listed on the Australian Securities
Exchange (MSB) and on the Nasdaq (MESO). For more information,
please see www.mesoblast.com, LinkedIn: Mesoblast Limited and
Twitter: @Mesoblast
Forward-Looking StatementsThis
press release includes forward-looking statements that relate to
future events or our future financial performance and involve known
and unknown risks, uncertainties and other factors that may cause
our actual results, levels of activity, performance or achievements
to differ materially from any future results, levels of activity,
performance or achievements expressed or implied by these
forward-looking statements. We make such forward-looking statements
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 and other federal securities laws.
Forward-looking statements should not be read as a guarantee of
future performance or results, and actual results may differ from
the results anticipated in these forward-looking statements, and
the differences may be material and adverse. Forward-looking
statements include, but are not limited to, statements about: the
initiation, timing, progress and results of Mesoblast’s preclinical
and clinical studies, and Mesoblast’s research and development
programs; Mesoblast’s ability to advance product candidates into,
enroll and successfully complete, clinical studies, including
multi-national clinical trials; Mesoblast’s ability to advance its
manufacturing capabilities; the timing or likelihood of regulatory
filings and approvals (including BLA resubmission), manufacturing
activities and product marketing activities, if any; the
commercialization of Mesoblast’s product candidates, if approved;
regulatory or public perceptions and market acceptance surrounding
the use of stem-cell based therapies; the potential for Mesoblast’s
product candidates, if any are approved, to be withdrawn from the
market due to patient adverse events or deaths; the potential
benefits of strategic collaboration agreements and Mesoblast’s
ability to enter into and maintain established strategic
collaborations; Mesoblast’s ability to establish and maintain
intellectual property on its product candidates and Mesoblast’s
ability to successfully defend these in cases of alleged
infringement; the scope of protection Mesoblast is able to
establish and maintain for intellectual property rights covering
its product candidates and technology; estimates of Mesoblast’s
expenses, future revenues, capital requirements and its needs for
additional financing; Mesoblast’s financial performance;
developments relating to Mesoblast’s competitors and industry; and
the pricing and reimbursement of Mesoblast’s product candidates, if
approved. You should read this press release together with our risk
factors, in our most recently filed reports with the SEC or on our
website. Uncertainties and risks that may cause Mesoblast’s actual
results, performance or achievements to be materially different
from those which may be expressed or implied by such statements,
and accordingly, you should not place undue reliance on these
forward-looking statements. We do not undertake any obligations to
publicly update or revise any forward-looking statements, whether
as a result of new information, future developments or
otherwise.
Release authorized by the Chief Executive.
For more information, please contact:
Corporate Communications / Investors |
Media |
Paul Hughes |
Sumit Media |
T: +61 3 9639 6036 |
Grant Titmus |
E: investors@mesoblast.com |
T: +61 419 388 161 |
|
E: grant@sumitmedia.com.au |
|
|
|
Rubenstein |
|
Tali Mackay |
|
E: tmackay@rubenstein.com |
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jul 2023 to Jul 2024